First CDK4/6 Inhibitor to Improve Survival in Metastatic Breast Cancer First CDK4/6 Inhibitor to Improve Survival in Metastatic Breast Cancer

Ribociclib plus standard-of-care endocrine therapy significantly improved overall survival for younger women with advanced hormone receptor-positive breast cancer vs endocrine therapy alone.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news